Antígeno prostático específico
Contenido principal del artículo
Resumen
El antígeno prostático específico, actualmente es el marcador más efectivo existente, dada su sensibilidad, utilidad para el diagnóstico, auxiliar para evaluar los efectos de diferentes tratamientos contra el cáncer de próstata y con utilidad pronóstica incluso.
En 1971 se iniciaron descripciones de sus propiedades, habiéndose encontrado, dado su constante estudio progresivamente más en ese sentido así como de sus aplicaciones.
Se encuentra tanto en plasma como en semen, pudiéndose alterar su concentración por causas diversas y su aumento no implica necesariamente cáncer prostático en forma absoluta. Su uso siempre debe aunarse a exploración digital prostática, alteraciones de cualquiera de ellos implica necesidad de efectuar biopsia de la glándula.
Su interpretación depende de la edad del paciente estudiado y cifras previas, así como el sitio prostático de instalación de una neoplasia existente y la presencia de metástasis. Algunas terapéuticas pueden causar falsos negativos.
Detalles del artículo
Cómo citar
Referencias
Lange Paul H. Localized prostate cancer: What tesis are still needed? AUA Today, May 1995;8(5):l-15.
Hara M, Koyanagi Y, lvone T et al. Some psyco-chemical characteristics of gamma seminoprotein an antigenic component specific for human seminal plasma forensic immunological study of body nuids and secretion. VII (En japonés). Nippon Horgalm Zasshi, 1971;25:322-324.
Wang MC, Valenzuela LA. Murphy GP, Chu TM. Purificalion of a human prestare specific antigen. lnvest Urol 1979; 17: 159-163.
Katz EA, Ohlsson CA, Raffo JA et al. Molecular staging of prostate cancer with the use oían enhanced reverse transcriptase PCR-Assay. Urology 1994;43:765-75.
Russell KJ, Dunator C, Hefermann MD et al. Prostate specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 1992; 1 O: 1208-17.
Hirotsugu Vemur, Hisayo Kitagawa. Senchero Ozono et al. Generation of anti-idiotype antibodies related to PSA, possible tools for treatment of prostate cancer. The J of Urol 1995;380: 153-4.
Chen Z, Prestigiacomo A, Stamey TA. Purification and characterization of PSA-ACT complex as a reference material for international standarization of PSA immunoassay, J of Urol 1995;269: 153-4.
Lilja H. A kallikrein-Likeseríne protease in prostatic fluid cleaves the predominnet seminal vesicle protein, J Clin lnvest 1985;76: 1899.
Oesrerting JE. Prostare specífic antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate, J of Urol 1991:907-923.
Elgamet AA, Billen J, Van de Voordew et al Extra prostatic sources of PSA, does it infer tbe subjective biochemical recurrence after radical prostecromy? J of Urol 1995;518A.
Aihara M. Goto Y, Sung Set al. What makes a cancer palpable. A comparíson of the pathological features of TIC and T2 prostate may releably identify residual viable prostate after cryosurgery. J of Urol 1995;513:519A.
Oesterling JE, Arbor Ann Manin SK et al. The periurethral glands do not have a clinically significant effect of the serum PSA concentration. J ofUrol 1995;153:518A.
Oesterling JE. Jacobsen SJ. Chute CG, Guess HA et al. Serum PSA in a community-based population of healthy men: Establishement of age specific reference ranges, JAMA l993;270:860-864.
Oesterling JE, Chen DW, Epstein JI et al. Prostate-specific antigen in the preoperative and postoperative evaluation of locolized prostatic cancer treated with radical prostatectomy. J Urol 1988;139:766-772.
Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostata specific antigen in serurn as a screening test for prostate cáncer. N Engl J Med 1991 ;324: 1156-61.
Stamey TA el al. PSA in the diagnosis and treatment adenocarcinoma of the prostate YY. Radical prostatectomy treated patients. J Urol 1989;141:1076.
Crawford ED, Shutz MJ, Cejan S, Drago J, Resniel MI, Chodak GW el al. The effect of digital rectal examinatíon of the prostate specific antigen levels. JAMA 1992;267:2227-2228.
Chybowski FM, Bergstralh EJ, Oesterling JE. The effect of digital rectal examination of the prostate specific antigen concentration: Results Oa A randomized study, J Urol 1992;148:83-86.
Oesterling JE, Jacobsen SJ, Klee O et al. Free complexed and total PSA: The establishment of appropiate reference ranges for their concentration and ratios, Sept 1995;154:1090-1085.
Westphal J. Meidernreich J et al. The impact of eyaculation on serum prostatic specific antigen. The J of Urol 1995; 153:464 A.
Stamey TA. Yang N, May AR, Mac JE, Freiha FS, Redwine E. Prostale specific antigen as a serum marker for adenocarcinoma of the prostate cancer. New Engl J Med 1887;317:909-916.
Hudson MA, Bahsen RR, Catalona WJ. Clinical use of prostate specific antígen in patients with prostate cáncer. J Urol 1989;142:1011-1017.
Catalona WJ, Stamey et al. Prostate specific antigen in prostatíc carcinoma. J Urol 1994;151:1283.
Witjes W, de Wiltdt JA. Rosier PF et al. Watchful waiting in patíents with sympthomatic benign prostatic hyperplasía: Clinical and urodynamical results. J of Urol 1995; 153:454A.
Partin AW et al. Prostatic speciflc antigen in the story of localized prostate cáncer: lnfluence of tumor differentiation tumor volumen and bening hyperplasia. J Urol 1990;143:747.
Natir O et al. Nuclear dexoxyrribonucleic acid ploidy and specific prostate antigen in operable prostatic adenocarcinoma. J Urol 1990: 144:203,
Oesterling JE, Andrews PE, Sumn UJ. Zinche H, Myers RP. Preoperative androgen deprivation therapy: artificial lowering of serum prostatic specific antigen without downstaging the tumor. J Urol 1993; 149:779-782.
Oesterling J et al. The use of prostate specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993;269:57.
Lange PH, Ercoli CJ, Lightner DJ, Fraley EE, Vesella R. The value of serum prostate specific antigen determination before and afler radical proslatectomy. J Urol 1989;141:873-879.
Hudson MA, Behson RR, Calalona WJ. Clinical use of prostatic specific antigen in patients with prostate cancer. J Urol 1989;142:1011-I017.
Catalona WJ, Lange HP, Andriole BC, Ballantine Carter H. Prostate specific antígen and prostate cancer. E.U.A. Annual Meeting, San Antonio, Tx, USA. Mayo 15, 1993.
Stormont TJ, Farrow GM, Myer RP et al. Clinical stage BO or tic prostate cancer: Non palpable disease identified by an elevated serum prostate specific antigen concentration. Urology 1993;41 :3-8.
Kabaian RJ, Menlin C, Kane R et al. The relationship of prostate specific antigen for digital rectal examination and transrectal ultrasonography: Finding of the American Cancer Society National Prostate Cancer Delection Project. Cancer 1992:69: 1195-1200.
Benort RM. Nashund MJ. An economic rationale for prostate cancer screening. Urology 1994;44:795-803.
Plawker MW, Fleisher JM, Nitli VM, Macchio. Primary care practition: An analysis of their perception of voiding disfuction and prostate cancer. J of Urol 1995;153:991.
Boring CC, Squires TS, Tong T. Cancer estátics 1992. CA cancer. J Clin 1992;42: 19-38.
Cupp MR, Oesterling JE. Prostate specific antigen, digital examination and trasrectal ultrasonography: Their roles in diagnosing early prostate cancer. J or Urol 1995;153:518.
Myers C, Cooper C, La Rocca R et al. Suranin: A novel growth factor antagonist with aictivity in hormone refractory metastatic prostate. Cancer J Clin Oncol 1992;10:881-889.
Giovannucci E. Ascherio A, Rimm EB. Coldistz GA, Stampler MJ, Millett WC. A prospective cohort study of vasectomy and prostate. Cancer in US men. 1993;267:873-877.
Oesterling JE et al. Prostate specific antigen. lmproving its abilily lo diagnose early prostate cancer. April 22/29. 1992;Vol. 267.
Cupp MR, Oesterling JE. Digital rectal examination. Prostatic specific antigen and transrectal ultrasonography: a proposal for their use in early detection of clinically significan, prostate cancer. lnvest Urol 1979;17:159-163.
Krakiewicz PJ, Bazinet M, Grudel C et al. Value of systemic transition zone biopsies. In: Early detection of prostate cancer. J of Urology 1995;153:296A.
Brower MK, Aramburu EAG, Chen GL. Preston SD, Ellis WJ. The inability of prostate specific antigen index to enhance the predictíve value of prostatic specific antigen in the diagnosis of prostate carcinoma. J Urol 1993; 150:369-373,
Stenman UH, Oesterling JE. lmpact of tumor doubling time and age based reference vllues for prostatic specific antigen on prostate cancer. Screening outcome. J of Urol 1995; l 53:505A.
Macindoe JH, Cooper CS, Perry PJ el al. The effect of exogenous testosterone on prostatic specific antigen levels. In: healthy young men. J of U rol 1995;397: 153,
Stephenson RA. Smart ChR, James BC et al. The fall. In: lncidence of prostate cancer on the down side of a prostatic specific antigen detection/screening induced peeck in incidence date from the Utah Tumor Registry. J of Urol 1995;416A: 153.
Boring CC, Squires TS, Long T. Cancer statistics, CA a cancer. Jo. urnal for Physicians 1992;42-19.
Metlin C. Early detection of prostate cancer following respected examination by multiple medalities: Reslts of the American Cancer Society National Prostate Cancer Detection Project. Clín lnvest Med 1993;16:440-447.
Chadwick DJ, Kemple T, Astley JP et al. Pilot study of screening for prostate cancer in general practice The Lancet 1991;338:613-616.
Labrie F, Dupont·A, Suburr R et al. Optimized strateg for detection of early stage, curable prostate cancer role of prescreening with prostate specific antigen. Clin lnvest Med 1994;16:425-439.
Esper Peg et al. Fat P: A new instrument for quality of life evaluation in prostate cancer. J of Urol 1995;153:239A.
Cooner WH, Mosley BR. Rutherford CI Jr, Beard JH, Pond HS, Terry JJ el al. Prostate cancer detection. In: A clinical urology practice by ultrasonography, digital rectal examination and prostate examination and prostate specific antigen, J Urol 1990; 143: 1146-1154.
Cooner WH. Prostate specific antigen, digital rectal examination, transrectal ultrasonographic examination of the prostate, In: Prostate cáncer detection. Monogr Urol 1991;12:2-13.
Catalona WJ, Smith DS. Retliff TL, Besler SD. The use of prostatic specific antigen based screening. JAMA 1993;270:948-954.
Montie JE, Severson RK, Porter A, Denneos RY. Observation on recent trends, In: The treutment of prostare cancer. Amongst elderly men, J of Urnl 1995: l 53:390A.
Rainwnter LM, Morgan WR, Klee GG, Zincke H. Prestare antigen specific testing in untreated and tremed prostatic adenocarcinoma. Mayo Clín Proc 1190:65: 118.
Hudson MA, Hahnson RR. Catalona WJ. Clinical use of prostatic specific antigen in patients with prostatic cancer. J Urol 1989;142:1011.
Lange PH et al. The valué of prostatic specific antigen determínation before and after radical prostatectorny. J Uro! 1989; 141 :873.
Oesterling JE. Prostaric specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:905.
Hammener P. Henke P, Hartmunt W et al. Preoperative evalúatíon of tumor agresiveness in patients with localizated prostate carcinoma. J of Urol 1995:153:428A.
Brown PN. Speights VO. Kuhi D et al. Prostatic specific anligen levels from completely sectioned Clinically bening, whole prostates. Cancer 1991;Ml:l592-1599.
Takayama TK. Versella RL. Lange PH. Newer applications of serum prostate specific antigen. In: The management or prostate cáncer. Sem Oncol 1994;44:785-803.
Babaian RJ. Kojima M. Ramirez El. Prostate specific antigen (PSA) density and age referenced PSA versus PSA alone. In: Early dection of prostate cancer. The J of Urol l 995;Vol. 153 ap. Supplement.
Elgamel AA, Van de Voorde WM, Van Poppel HP et al. Selective zonal distribution of tumor volume vs grade. In: Tic prostate cáncer. J Urol 1995;153:484A .
Stranley TA. Kubalin JN. Prostate specific antigen. In: The diagnoses and treatment of carcinoma of the prostate. 1. Untreated patients. J Uml 1989:1070-1075.
Browcr MK. Chatner MP. Bealie J. Buchner DM, Vesselle RL. Lange PH. Screening for prostate carcinoma with prostatic specific antigen. J Urol : 147:841-845.
Levesque P, Hirschorn M, Noisseaux S et al. Radiolabelled monoclonal unibody III-cyt-356 localice extraprostatic recurrence after prosratectomy. J of Urol 1995:153:519A.
Liu S. Miller PD, Holmes SaV, Cristmas TJ, Kirby RS. EosinophiIlic prostatitics and prostatic specific antigen. Br J Urol 1992;69:61-63.
Carter HB. Morell Ch. Pearson JD et al. Stimation of prostatic growth using serial prostate specific antigen meassurement. In: Men with and with out prostate disase. Cancer Res (1992;52:3323-3328.
Rees MA, Mc Hugh TA, Dorr RP et al. Assessment of the utility of bone scan. CT sean and lymph node dissection. In: Staging of patiennts with newly diagnosed prostate cancer. J of Urol 1995;153:352A.
Catalona WJ. Smilh DS. Retliff TL. Dodds KM, Copler DF, Yuan JJ et al. Meassurement of prostate specific antigen. In: Serum as a screening test for prostate cancer. N Engl J Med 1991 ;324: 1156-1161.
Sterman UH. Kneth P, Aromas A et al. Setum prostatic specific antigen increases 6-1O years before diagnosis of prostate cancer. J of Urol 1995;269: 153-4.
Kirkels WJ. Kranse R. Bílijenberg G et al. Prostate biopsies and cancer detection rates. In: Men with low serum prostatic specific antigen levels. J of Urol 1995:297: 153-4.
Parra OR. Radical perineal prostatectomy with out pelvic lymphadenectomy: Selection criteria and early results. J of Urol 1995;240A: 153.
Carroll PR. Current aproach to the initial staging of prostaté cancer and an evaluation of cryosurgery and neodyuvant androgen deprivation before definitive treatment early detection and treatment of prostale cancer. AUA Annual Meeting. Apr 1995. Evening Seminar 1995.
Naraghi R, O'Donnell WF, Bahnson RR. Routine frozen section of pelvic lymph node specimens prior to radical retropubic prostatectomy is unnecessary in patients with prostate specific antigen levels less than 20 ng/mL, J of Urol 1995,353A: 153.
Flanningan R. Mc Kay T. Olson M et al. Preoperative CT scanning for the evaluation of lymph node metastacis in patients before radical prostatectomy. J of Urol 1995;153:355.
Thomas R, Steele R, Ahuja S. Evoluting role of laparoscopy. In: The management of prostate cancer: A one institution-one surgeon's experience. J of Urol 1995, 153:481.
Matzkin H et al. Significado pronóstico de los cambios de los marcadores prostáticos específicos, después del tratamiento endocrino del cáncer prostático estadio D2. Cancer 1992;70(2):302-2309.
Smith DS, Calalona WJ. Effect of longitudinal screening on detection rate and stage of prostate cancer. The J of Urol 153. Ap. 1995;417A:495-573.
Campbell SC, Piedmont MR, Klein EA. Pelvic lympth node specimenes prior to radical proslalectomy is unnecessary in patients with prostate specific antigen less than 20 ng/mL. J of Urol 1995; 153:353A.
Douglas TH, Sosterhenn IA, Moul JW, Lead G. The significance of prostatic specific antigen detected nonpalpable adenocarcinoma of the prostate (stage Tlc). The of Urol 1995;1S3:25 I.
Stewart E, Stamey G, Stamey TA. Pathological characteristics of nonpalpable and palpable prostate cancer with hybritech prostatic specific antigen specific antigen of 4-I0 ng/mL. J of Urol 1995;513:5l7A.
Soble JJ, Basler JW. Alkaline phosphatase an effective and cost controlling determinant. In: Prostate cancer Staging. J of Urol 1995;153:354A.
Volf JS, Shinohera K, Kelekowke KW et al. Selection of patients for laparoscopic pelvíc lymphadectomy prior to radical prosratectomy: A decision analysis. Urology 1993;42:630-88.
Chybowisky FM, Keller JJL. Begstralh EJ et al. Predicling radionuclide bone scan findings in patients with newsly diagnosed unlreated prostate cancer: Prostale specific antigen in superior to all other clinical parameters. J Urol 1991;145:313-318.
Russell KJ, Dunetor C. Hafermann MD et al. Prostate specific antigen. In: The management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. J Urol 1991 ;146: 1046-52.
Ritler MA, Messing EM, Shanahan TG, Potts S, Chappell RJ, Kinsells TJ. Prostate specific antigen as a prediction of radiotherapy response and patterns of failure. In: Localized prostate cancer. J Clin Oncol 1992;10:1208-17.
Sanders H. Smith Edwin, Vooduvard M, Graham SD. The use of prostatic specific antigen to predict bone metastases. In: Recurrence after definitive local therapy for prostate cancer. J of Urol 1995;238: 1153.
Fenover JS. Effects of testosterone supplementation. In: The aging male. J Clin Endocrinol Metab 1992;75:1092-1098.
Oesterling JE, Milem O, Nashville TN et al. Serial prostatic specific antigen measurements in patients with clínical HPB enrolled in a randomized, double blind, placebo controlled study with terazocine. J of Urol 1995 ;396A: 143-4.
Benson MC, Whang IS, Olsson CA, Muhon CA, Mahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostatic specific antígen. J Urol l992;147:817-821.
Jacob G. Ashutush T, Joseph P et al. Differential supression of prostatic acid phosphate (PAP) and prostate specific antigen by finesteride. J of Urol 1995;153(4):300.
Guess HA, Heyse JF, Gormley GJ. The effect of finesteride on prostalic specific antigen. In: Men with benign prostatic hyperplasia. Prostate 1993;22:31-37.
Stoner E. The finesteride study group. The clinical effects of a 5 alfa reductase inhibitor, finesteride of benign prostatic hyperplasia J Uro) 1993;147: 1298-1302
Gonnley GJ. The effect of finesteride. In: Men with benign prostatic hyperplasia. N Engl J Med 1992;327:1185-1191.
Worldstreicherr J, Tocker PF, Chang J, Oesterling JE et al. The effects of finesteride on serum prostatic specific antigen. In: Men with benign prostatic hyperplasia. J or Urol 1995;396A:153-4.
Beck MA, Tocher PF, Malice MP et al. The effect of finesteride on serurm prostatic specific antigen. In: Men with prostatic hyperplasia and prostate cancer. J Urol 1995;153(4):397.
Jacob G, Ashutesh T, Joseph P et al. Differential supression of serum prostatic acid phosphatase and prostate specific anligen by finesteride. J Urol 1995;153:300A .
Farr WR. Wang Vu, Cohen D et al. Neoadjuvanc androgen deprívation therapy (ADT) in patients clinically localized prostate cancer-effect on (+) margins and postoperative prostatic specific. J of Urol 1995; 153:311A .
Lerner SE, Blufe ML, Erckhorlt JT et al. Analysis or rísks factors for progression in patients wlth pathologically confined prostate cancers after radical retropubíc prostatectomy. J of Uro! 1995;153:390A.
Panin AW, You J. Caner AB et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage, In: Men with localized prostate cancer. J Urol 1993;150:I I0-4.
Wolf Jr JS, Shinohara K. Carroll PR, Narayan P. Combinand role of transrectal ultrasonography, Gleason score and prostare specific antigen. In: Predicting organ-confined prostate. Urology 1993;42:131-7.
Kleer E. Larson-Keller JJ. Zincke H, Oesterling JE. Ability of preoperarive serum prostate specific antigen value to predict pathological stage and DNA ploidy. lnfluence of clinical srage and tumor grade. Urology 1993;41:207-16.
Fleshner NE. Feir W. Further experíence with sequential androgen blochade. J Urol 1995; l 53:449A.
Seckin B, Anthony CT, Murphy B et al. Can antigen prostatic specific be used as a valid end point for chemotherapy efficacy. In: Advanced cancer and urodynamical results, J Urol 1995;153:454A.
De Clerk J. Radionuclide therapy of bone metastases with Ra-186- HEDP. J Urol 1995;153:240A.
Stamey TA, Ferrari MK. Schmidt DS. The value of serial prostate specific determinations 5 years after radiotherapy: Steephy increasing values characterize 80% of patients. J Urol 1993; 150: 1856-59.
Babaían RJ, Kozime M, Saiton M, Ayala AG. Detection of residual prostate cáncer after external radiotherapy: Role of prostate specific antigen and transrectal ultrasonography. J U rol 1995, 153:518A.
Schmidt JD, Parsons L, Casola G et al. Transperineal cryoablalion for prostate cancer. J Urol 1995;153:502A.
Cronaver MV, Reíssigi A, Elder I et al. lncreased bPGF serum levels. In: patients suffering from BPP-1 and prostate cáncer. J Urol 1995,153:482A.
Cohen JK, Miller RJ, Shuman BA. Cryosurgical ablation of the prostate patterns of failure and two year post treatment data as comparted to external beam radiation therapy. J Urol 1995;153:503A.
Parivar F, Kurkanewicz J, Hyricak H et al. Protón magnetic resonance spectroscopy of prestare may reliably identify residual viable prostate after cyosurgery. J Urol 1995;513:519A.
Kinne DW, Kopans DB. Physical examination and mammographyn in the diagnosis of breast disease, In: Harris Jr et al. Breast disease. Philadelphia JB. Lippincot Company 1987:54-86.
Stamey TA, Making. The most out of six sextant biopsies. Urology 1995;45:2-12.
Epstein JI. Pathology of prostntic intraepithelial necplasiu and adenocarcinoma of the prostate: Prognostic influences of stage. tumour volume, grade and margins of resection. Sem Oncol 1994;2 I :527-541.
Isa.aes WB, Bova GS, Morton MJG et al. Molecular biology of prostate cancer. Sem Oncol 1994;21 :514-52 l .
Stamey TA, Yang N, Hay AR, Me Neal JE, Freiha FS, Redwine E. Prostate specific antigen as a serum marker for a adenocinoma of the prostate. N Engl J Med 1987;817:909-916.
Scardino PT. Rationale for the treatment for clinically localiced prostate cancer. Early detection and treatment or prostate cancer. EUA Annual Meeting, April 26. 1995.
Bagma CH, Wim CP. Frtz H. Serial prostatic specific antigen measurement and progression. In: Untreated confined (TO-3Nx. Mo Gl-3), carcinoma of the prostate J Uml 1995;153:2.51-91.